Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer

The occurrence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been reported after treatment with cytotoxic alkylating agent–based chemotherapy for solid tumors. We report a patient with metastatic ovarian carcinoma treated with carboplatin and paclitaxel, who developed secondary acute erythroid leukemia. The overall survival of patients with stage III and IV ovarian cancer has increased in the past decade. Monitoring of the long-term outcome of paclitaxel- and platinum-based regimens is warranted, particularly with regard to monitoring the development of secondary MDS and/or AML. The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed.

[1]  H. Kantarjian,et al.  Therapy-related leukemia and myelodysplastic syndrome. , 1987, Seminars in oncology.

[2]  A. Mazard,et al.  Kinetics of the reaction of cis-platinum compounds with DNA in vitro. , 1985, Biochemical and biophysical research communications.

[3]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[4]  P. Hall,et al.  Risk of leukemia after platinum-based chemotherapy for ovarian cancer. , 1999, The New England journal of medicine.

[5]  M. Shah,et al.  Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Thigpen.  Chemotherapy for advanced ovarian cancer: overview of randomized trials. , 2000, Seminars in oncology.

[7]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[8]  R. Larson,et al.  Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. , 1988, Blood.

[9]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[10]  F. Muggia.  Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. , 2004, Seminars in oncology.

[11]  T. Thigpen.  First-Line Therapy for Ovarian Carcinoma: What's Next? , 2004, Cancer investigation.

[12]  Alberts,et al.  New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors. , 1998, The oncologist.

[13]  L. Mele,et al.  The incidence of secondary leukemias. , 1999, Haematologica.

[14]  J. Lotz,et al.  High dose chemotherapy in ovarian cancer , 2001, Oncology.

[15]  D. Gilliland,et al.  Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia , 1997, Bone Marrow Transplantation.

[16]  F. Picard,et al.  Erythroleukemia: a need for a new definition , 2002, Leukemia.

[17]  H. Koeffler,et al.  Secondary myelodysplastic syndromes and leukemias. , 1994, Current opinion in hematology.

[18]  M. Voso,et al.  Therapy Related Leukemias: Susceptibility, Prevention and Treatment , 2001, Leukemia & lymphoma.

[19]  J. Seymour,et al.  Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy , 1999, Leukemia.

[20]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.